BAXTER INTERNATIONAL INC

Baxter International Inc. announced the resignation of Anita Zielinski, who served as the company's Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, and Controller. Her departure is effective September 15, 2026, as she is moving to another company. The company clarified that her resignation was not a result of any disagreement with management or the board regarding operations, policies, financial disclosures, or accounting matters.

Baxter International Inc. has commenced cash tender offers to purchase up to $500 million of its outstanding senior notes. The offers target four series of notes: 3.132% due 2051, 3.500% due 2046, 4.500% due 2043, and 2.539% due 2032. The tender offers aim to manage the company's debt structure, with an early tender premium offered to encourage participation.

Baxter International reported increased net sales and operating income for the second quarter of 2026. Net sales rose to $2.96 billion, with net income attributable to stockholders reaching $126 million. For the first half of 2026, cash flow from continuing operations significantly improved to $510 million. The company also noted ongoing legal proceedings related to its Novum LVP product and a reduced quarterly dividend.

Baxter International Inc. reported strong second-quarter 2026 results, with sales reaching $2.96 billion, a 5% increase on both reported and organic bases. The company achieved U.S. GAAP diluted EPS of $0.26 and adjusted diluted EPS of $0.56, exceeding expectations. Following this performance, Baxter raised its full-year 2026 financial outlook for sales and adjusted EPS. Additionally, the Board of Directors declared a quarterly cash dividend of $0.01 per share.

Baxter International Inc. has restructured its operating model, changing its reportable segments from three to two, effective Q2 2026. The new segments are Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST), with the former Pharmaceuticals segment now integrated into MPT. The company is furnishing recast historical financial information for comparability, which does not impact previously reported consolidated net income or EPS.

Baxter International Inc. approved a new Executive Severance and Change in Control Plan, effective May 4, 2026, which supersedes the prior plan and expands the definition of "Qualifying Termination." The new plan establishes tiered severance benefits for Vice Presidents and above, including named executive officers, for both non-Change in Control and Change in Control terminations. Additionally, an amendment to CEO Andrew Hider's offer letter was approved, increasing his lump-sum cash payment for medical, dental, or vision coverage from 18 to 24 months in a non-CIC qualifying termination.

Baxter International Inc. reported Q1 2026 net sales of $2.701 billion, a 2.9% increase year-over-year. However, the company posted a net loss attributable to stockholders of $(15) million, or $(0.03) diluted EPS, compared to a net income of $126 million and $0.25 diluted EPS in Q1 2025, primarily due to the prior year's gain from the Kidney Care divestment. Cash flows from continuing operations significantly improved to $213 million. The company also faces ongoing legal and regulatory matters, including Class I recalls for its Novum LVP and multiple lawsuits.

Baxter International Inc. reported first-quarter 2026 sales from continuing operations of $2.7 billion, a 3% increase on a reported basis but a 1% decline organically. Adjusted diluted EPS from continuing operations was $0.36, a 35% decrease year-over-year, impacted by unfavorable comparisons and higher costs. The company reiterated its full-year 2026 financial outlook and declared a quarterly cash dividend of $0.01 per share. Strategic highlights included new product introductions and expansion of its continuous improvement system.